Compare LPA & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | NTHI |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Costa Rica | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.3M | 106.0M |
| IPO Year | 2023 | 2023 |
| Metric | LPA | NTHI |
|---|---|---|
| Price | $2.88 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 24.4K | ★ 177.7K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,990.00 |
| Revenue This Year | $6.83 | N/A |
| Revenue Next Year | $18.35 | N/A |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.04 | $2.96 |
| 52 Week High | $4.73 | $12.99 |
| Indicator | LPA | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 43.54 |
| Support Level | $2.85 | $3.03 |
| Resistance Level | $3.27 | $3.70 |
| Average True Range (ATR) | 0.14 | 0.34 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 45.34 | 36.84 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.